Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar on Tuesday, October 22, 2024, at 8:00 a.m. ET to share achievement of in vivo preclinical proof of concept data and business development and financial updates. Webinar Presentation Details: The live and archived webcast of the Company's webinar presentation will be accessible through this webcast link, or through the Ev ...